Artificial Intelligence News for July 17 2017

Google Ventures CEO on the Future of Artificial Intelligence(AI) and Life Sciences
http://www.youtube.com/watch?v=plj60Y7QKZY
Bill Maris, Google Ventures president and chief executive officer, discusses venture capital opportunities in life sciences, the criticisms of Theranos and the future …

Artificial Intelligence Is The Real Thing For Pharma And Medtech

Artificial intelligence might seem more the preserve of computer nerds and tech giants than pharma companies. According to Boehringer Ingelheim’s global chief data scientist, Philipp Diesinger, “The entire industry is looking at data science and AI”. This increased focus on data could drastically change the way drugs are developed and paid for. AI will be vital if outcomes-based healthcare is to be successfully implemented, pointed out Philips’ chief innovation & strategy officer, Jeroen Tas, who also stressed that AI really signaled a new way of handling data. He described AI as “The way you interpret data. You constantly stream the data and add that data to the body of knowledge,” he told EP Vantage during the AI Summit in London in May. “That’s not the case today, because it’s all in the head of the doctor.” Boehringer’s Mr. Diesinger believes that what is new is the “Combination of AI, big data and new perceptions of these deep analytical methods”, as well as an increasing capacity for data storage and processing. The German company has been active in AI for around two years, and is using data to reduce the cost of drug development and enable earlier go/no-go decisions on pipeline candidates. According to Mr. Diesinger, the group wants to evolve from a pharma to a holistic healthcare company, with the help of AI. Meanwhile, Philips has been narrowing its focus from technology in general to medtech alone – and has gone big on connected devices and data processing. Oncology is one area where pharma companies are already employing AI. Notably, Novartis, which has also been involved in AI for two or three years, recently signed a deal with IBM Watson to explore the technology’s use in breast cancer care. The project will analyse data from existing electronic health records using Watson’s AI expertise. As for Boehringer, Mr. Diesinger would only give one example of its AI projects: the Angels Initiative, a joint venture with the European Stroke Organisation that gathers anonymous time stamp data from hospitals to reveal patterns in stroke care and identify potential pinch points. Also looking for patterns is London-based BenevolentAI, which hopes its machine-based learning approach to processing academic research, clinical studies and other health-related data will help identify correlations in data that could lead to new drugs and significantly speed up the process of drug development. With plenty of other companies clamoring to get into healthcare, including tech giants like IBM Watson and Alphabet, how will medtech and pharma groups compete in the AI space? There are still issues to be ironed out, including cybersecurity dangers, illustrated by the ransomware attack in May that hit the UK’s NHS as well as a recent report by the US Health Care Industry Cybersecurity Task Force highlighting the challenges the industry faces. Mr. Diesinger of Boehringer agrees that overall, the pharma sector is a “Couple of years behind other industries” in terms of using AI. But he feels that that could soon begin to change, particularly if healthcare spending comes under more pressure, forcing the sector to become more streamlined.
more…

Artificial Intelligence in Medicine – ScienceDirect.com

The online version of Artificial Intelligence in Medicine at ScienceDirect.com, the world’s leading platform for high quality peer-reviewed full-text journals.
more…

Google’s artificial intelligence chief says ‘we’re in an AI spring’

“We’re kind of in an AI Spring,” says John Giannandrea, Google’s head of machine learning. During a Google I/O panel on Friday held at the company’s developer’s conference, Giannandrea was joined by Google SVP of Product Aparna Chennapragada and Google Brain lead Jeffrey Dean to talk about how AI and machine learning are changing products. Giannandrea cited the recent success in the areas of speech recognition and image understanding as two reasons AI and machine learning are suddenly so hot. Success in speech recognition and image understanding are two reasons AI and machine learning are suddenly so hot. TensorFlow, which is an open source library for machine intelligence.
more…

Which movies get artificial intelligence right? | Science …

Take Science ’s quiz and test your knowledge of AI in the movies! In the opening scene of the 1982 film Blade Runner, an interrogator asks an android named Leon …
more…

Center for Internet and Society

The Center for Internet and Society, along with the Stanford Law and Technology Association, and the Stanford Technology Law Review bring together four scholars who have begun to examine the near term, short term, and long term ramifications of artificial intelligence for law and society. Moderator: Ryan Calo, Director of Privacy and Robotics at CIS. Ian Kerr: Prior to his appointment to the Faculty of Law at the University of Ottawa in 2000, Ian Kerr held a joint appointment in the Faculty of Law, the Faculty of Information & Media Studies and the Department of Philosophy at the University of Western Ontario. John O. McGinnis: Professor John O. McGinnis is a graduate of Harvard College and Harvard Law School where he was an editor of the Harvard Law Review. Professor Solum received his J.D. magna cum laude from Harvard Law School and received his B.A. with highest departmental honors in philosophy from the University of California at Los Angeles. Mary-Anne has a PhD in Computer Science and a Masters in Law, and is a leading authority in Knowledge Representation and Reasoning with transdisciplinary strengths in Software Engineering, Artificial Intelligence, Risk Management, Cognitive Robotics and Law.
more…

powered by Zaphne